08:00 , Jan 13, 2014 |  BC Week In Review  |  Clinical News

Cevira regulatory update

Photocure said FDA denied the company's request to grant Fast Track designation to Cevira to treat HPV infection in women with cervical intraepithelial neoplasia (CIN) grade 2. Photocure said FDA's decision is based on a...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Cevira: Final Phase IIb data

Final data from a double-blind, international Phase IIb trial in 262 patients with cervical intraepithelial neoplasia (CIN) 1/2 showed that 5% intravaginal Cevira improved the 6-month disease clearance rate of HPV types 16 and 18...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Clinical News

Cevira: Phase IIb data

A double-blind, international Phase IIb trial in 262 patients with cervical intraepithelial neoplasia (CIN) 1/2 showed that 5% intravaginal Cevira non-significantly improved the 3-month disease clearance rate (73% vs. 60%, p=0.2) and the clearance rate...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Company News

Photocure dermatology news

Photocure said it will exit its Allumera cosmetic dermatology business in the U.S. by the end of this year because the business has not delivered the growth potential it had expected. In June 2011, Photocure...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Clinical News

Cevira: Completed Phase IIb enrollment

Photocure completed enrollment of 240 patients with low to moderate grade cervical intraepithelial neoplasia (CIN) in a placebo-controlled, dose-finding, U.S. and European Phase II trial evaluating intravaginal Cevira. Photocure ASA (OSE:PHO), Oslo, Norway   Product:...
07:00 , Jun 27, 2011 |  BC Week In Review  |  Clinical News

Cevira: Phase II started

Photocure began a placebo-controlled, dose-finding, U.S. and European Phase II trial to evaluate intravaginal Cevira in 240 patients with low to moderate grade cervical intraepithelial neoplasia (CIN). Photocure ASA (OSE:PHO), Oslo, Norway   Product: Cevira...
08:00 , Jan 31, 2011 |  BC Week In Review  |  Clinical News

Cevira: Additional Phase IIa data

Additional data from a Phase IIa trial in 70 patients with low-grade cervical lesions showed that Cevira led to a significantly greater 6-month disease clearance rate as measured by Pap smear vs. placebo (57% vs....
07:00 , Oct 18, 2010 |  BC Week In Review  |  Clinical News

Cevira: Preliminary Phase II data

Preliminary data from a Phase II trial in 70 patients with mild cervical abnormalities showed that Cevira produced a 3-month disease clearance rate as measured by Pap smear of 71% vs. 43% for placebo. No...
07:00 , Mar 18, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Not applicable In vitro and chick embryo studies identified light-activated boron dipyrromethene compounds that could help treat cancer. In three human cancer cell lines,...
07:00 , May 11, 2009 |  BC Week In Review  |  Clinical News

Cevira: Phase I/II started

PhotoCure disclosed that last quarter it began a 12-month, double-blind, placebo-controlled, European Phase I/II trial to evaluate Cevira in 70 patients. PhotoCure ASA (OSE:PHO), Oslo, Norway   Product: Cevira   Business: Cancer   Molecular target:...